Status:

COMPLETED

Pediatric Ease of Use ELLIPTA Items

Lead Sponsor:

GlaxoSmithKline

Collaborating Sponsors:

RTI Health Solutions(RTI HS)

Conditions:

Asthma

Eligibility:

All Genders

5+ years

Brief Summary

A range of devices has been developed to administer inhaled therapy for asthma, including dry powder inhaler (DPI) devices. ELLIPTA is a DPI that is preloaded with a drug therapy to treat asthmatic su...

Eligibility Criteria

Inclusion

  • Child inclusion criteria
  • Be 5 to 11 years of age
  • Have asthma
  • Currently use a maintenance inhaler to treat their asthma
  • Be willing and able to provide assent
  • Be willing and able to participate in a 45-minute interview in English Caregiver inclusion criteria
  • Above 18+ years of age
  • Be a caregiver (parent or legal guardian) of a pediatric subject with asthma that meets the criteria above
  • Be willing and able to provide signed and dated informed consent and parental permission in English
  • Be willing and able to participate in a 45-minute interview

Exclusion

  • Nil

Key Trial Info

Start Date :

October 17 2017

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

December 1 2017

Estimated Enrollment :

28 Patients enrolled

Trial Details

Trial ID

NCT03315572

Start Date

October 17 2017

End Date

December 1 2017

Last Update

January 28 2019

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

GSK Investigational Site

Southfield, Michigan, United States, 48034

2

GSK Investigational Site

Raleigh, North Carolina, United States, 27612